Lipopolysaccharide Antagonists Block Taxol-induced Signaling in Murine Macrophages

By Carl L. Manthey,* Nilofer Qureshi,† Peter L. Stütz,‡ and Stefanie N. Vogel*

From the *Department of Microbiology, Uniformed Services University of the Health Sciences, Bethesda, Maryland 20814; the †Mycobacteriology Research Laboratory, William S. Middleton Memorial Veteran’s Hospital, Madison, Wisconsin 53705; the ‡Department of Bacteriology, School of Agriculture and the Life Sciences, University of Wisconsin, Madison, Wisconsin 53706; and the §Sandoz Research Institute, A-1235 Vienna, Austria

Summary
Taxol is the prototype of a new class of microtubule stabilizing agents with promising anticancer activity. Several studies show that taxol mimics the actions of lipopolysaccharide (LPS) on murine macrophages. To investigate the mechanism of taxol-induced macrophage stimulation, we evaluated the ability of *Rhodobacter sphaeroides* diphosphoryl lipid A (RsDPLA) and SDZ 880.431 to block taxol-induced effects. RsDPLA and SDZ 880.431 are lipid A analogues that lack LPS-like activity, but inhibit the actions of LPS, presumably by blocking critical cellular binding sites. We report that RsDPLA and SDZ 880.431 potently inhibited taxol-induced TNF secretion, gene activation, and protein-tyrosine phosphorylation. The role of microtubules in taxol signaling was investigated. Taxol-induced microtubule bundling in primary and transformed RAW 264.7 macrophages was not blocked by RsDPLA or SDZ 880.431. Taxotere, a semisynthetic taxoid, was more potent than taxol as an inducer of microtubule bundling, but did not induce tumor necrosis factor α secretion and gene activation. These data dissociate the microtubule effects of taxol from macrophage stimulation and suggest that taxol stimulates macrophages through an LPS receptor-dependent mechanism. The results underscore the potential of taxol as a tool for studying LPS receptor activation and provide insights into possible therapeutic actions of this new class of drugs.

Mammalian host defense mechanisms have evolved to recognize trace amounts of Gram-negative bacterial outer membrane, namely, endotoxin, and to respond in an integrated fashion involving each major effector arm of the immune system (1). In extreme cases, autonomic systems involved in homeostasis are dysregulated, as occurs during septic shock (2). Despite the complexity and potential violence of this response, only recently has there been significant understanding of how endotoxin interacts with cells at the molecular level (3, 4). The major component of endotoxin, i.e., LPS, appears to exist in the extracellular milieu as a complex with one or more plasma proteins. Select proteins increase the efficiency of LPS binding to CD14, a phosphatidylinoositol-anchored membrane protein expressed by macrophages and neutrophils (5–9). Delivery of LPS to CD14 is required (8, 9), but not sufficient, for LPS stimulation of macrophages. This is illustrated by the finding that the inactive lipid A analogue, lipid IVα, suppresses LPS signaling under conditions that do not block LPS binding to CD14 (9). Consequently, it has been speculated that CD14 serves to facilitate delivery of LPS to an as yet unidentified LPS “receptor” protein (4). Identification of this putative receptor is an area of active investigation.

Taxol1 is the first effective anticancer agent with a novel mechanism of action to be developed in over a decade, and it has generated considerable enthusiasm in the oncology community due to its favorable response rate in patients with advanced metastatic ovarian, breast, and lung cancer (10). Taxol is a complex diterpenoid isolated from the bark of the Pacific yew (Fig. 1). The antiproliferative effects of taxol appear to be related to its ability to bind β-tubulin and stabilize microtubules (11–13). The dynamic depolymerization necessary for microtubule function during mitosis (and other cellular processes) is blocked. Taxol-treated cells develop large bundles of microtubules and multiple mitotic asters and are arrested in the M phase of the cell cycle (14). Numerous taxol analogues have been generated by semisynthetic approaches (13, 15). One of these, taxotere2, is approximately twice as po-

---

1 World Health Organization generic name is paclitaxel.
2 World Health Organization generic name is docetaxel.
tent as taxol in cytotoxicity and microtubule depolymerization assays (15) and is also being tested in clinical trials (16).

Nature may have provided in taxol an invaluable tool for dissecting LPS-signaling pathways. Ding et al. (17) discovered that taxol exhibited profound cell cycle–independent effects on murine macrophages. Taxol activated the acute internalization of TNF-α receptors and initiated a slower induction of TNF-α protein, properties that were remarkable, in part, because they were shared by LPS. Further investigation revealed that this activity of taxol was restricted to macrophages from mice bearing the wild-type Lps gene, i.e., responsiveness to taxol was genetically linked to responsiveness to LPS. Subsequently, taxol was shown to stimulate a panel of macrophage responses in a manner virtually identical to LPS (18–20). Taxol activated the expression of six of six LPS-inducible genes with kinetics and amplitude indistinguishable from LPS, and taxol, like LPS, induced rapidly the tyrosine phosphorylation of several 41–45-kD proteins (18, 20). In toto, the overlapping activities of taxol and LPS suggest the two agents share signaling pathways. Recently, Ding et al. (21) have presented the provocative finding that LPS binds specifically and with high affinity to β-tubulin, providing a potential mechanism by which taxol and LPS could induce shared responses.

A second set of tools useful in studying LPS signaling include several synthetic/natural lipid A and lipid X analogues that lack LPS-like activity, but that retain the ability to block LPS stimulation of various cell types. It is believed that they represent competitive inhibitors of LPS binding to its critical receptor(s) due to their structural similarity to the active center of LPS, namely, lipid A, and because they are highly specific inhibitors of LPS (i.e., they do not block other macrophage activating agents such as Gram-positive cell walls, phorbol ester, or cytokines [9, 22, 22a]), and can be overridden in the presence of excess LPS (9, 22–25). Rhodobacter sphaeroides diphosphoryl lipid A (RsDPLA)3 is one of the best characterized LPS “antagonists” (Fig. 1). Initially purified by Takayama et al. (26) and chemically defined by Qureshi et al. (27), RsDPLA has been used to block LPS-induced TNF production in vivo (28) and by monocytes/macrophages in vitro (22, 26, 28, 29). Others have reported that RsDPLA blocks LPS-induced pre-B cell activation (23) and CD18 surface expression on human neutrophils (24). In addition to other lipid A analogues, several synthetic monosaccharide derivatives also have inhibitory activity (25, 30). SDZ 880.431 (3-aza-lipid X 4-phosphate) (Fig. 1) has been well characterized and shown to inhibit LPS-induced macrophage TNF secretion (31), neutrophil CD18 expression (25), and expression of procoagulant activity in cultures of human PBMC (30). In general, disaccharide inhibitors are approximately an order of magnitude more potent than monosaccharide inhibitors.

In the present study, we investigated further the relationship between taxol- and LPS-signaling pathways. We have used RsDPLA and SDZ 880.431 as tools to suggest that taxol stimulates murine macrophages through an LPS receptor–dependent pathway, and to dissociate taxol-induced signaling from taxol-induced microtubule changes.
40; 1 mM Na3VO4; 50 mM NaF; 100 μM TPCK; 100 μM quercitin; 1 mM PMSF; 1 μg/ml leupeptin, and pepstatin). Culture plates were agitated in an ice water bath for 10 min, and cell lysates were transferred to microfuge tubes and centrifuged (12,000 g for 1 min) to remove detergent-insoluble material. Supernatants (80 μl) were boiled for 5 min with 28 μl of 4 X loading buffer (200 mM Tris-HCl, pH 6.8, 10% SDS, 400 mM dithiothreitol, 40% glycerol, and 0.4% bromophenol blue), and 13 μl/lane was resolved by SDS-PAGE on 10% acrylamide gels (7 x 8 cm). The separating gel was buffered with 375 mM Tris-HCl, pH 8.5. Resolved proteins were blotted onto Immobilon-P transfer membranes (Millipore Corp., Bedford, MA). Blots were blocked 1 h in wash buffer (20 mM Tris-HCl, pH 7.6, 137 mM NaCl, and 0.1% Tween 20) containing 3% gelatin and 5% milk. Blots were then incubated 1 h in wash buffer containing 1 μg/ml antiphosphotyrosine mAb (clone 4G10; Upstate Biotechnology, Inc., Lake Placid, NY), washed, and incubated with horseradish peroxidase-conjugated goat anti-mouse IgG (1:3,000 dilution; Bio-Red Laboratories, Richmond, CA). Binding of secondary antibody was detected with the enhanced chemiluminescence (ECL) detection method (Amersham, UK). Molecular weights of phosphoproteins were determined by comparison with prestained markers (Bio-Rad Laboratories).

Immunofluorescent Detection of Microtubules. RAW 264.7 cells (American Type Culture Collection, Rockville, MD) (maintained in DMEM containing 5% FCS) or primary macrophages were plated (2 x 10^5 cells/well) onto Lab-Tek eight-well glass chamber slides (Nunc, Inc., Naperville, IL). RAW 264.7 cells were allowed to adhere and proliferate overnight. Cells were then pretreated 10 min with media alone or containing 2 μg/ml RsDPLA or 20 μg/ml SDZ 880.431. Where indicated, culture media was adjusted to contain 3 μM taxol, and the cells were cultured an additional 4 h before fixation for 30 min at room temperature in 10% buffered formalin. Microtubules were visualized in fixed cells by immunofluorescence as described previously (18) using a rabbit anti-sea urchin tubulin IgG fraction (Polysciences, Inc., Warrington, PA) and a fluoresceinated F(ab')2 fragment of goat anti-rabbit IgG (Cappel Laboratories, Malvern, PA).

Results

Taxol-induced TNF Secretion Is Blocked by Lipid A-based LPS Inhibitors. As a first approach to define the signaling mechanism of taxol, the ability of RsDPLA to inhibit taxol-induced TNF secretion was evaluated. C3H/OuJ macrophages were treated with medium alone or medium containing 30 μM taxol with or without increasing concentrations of RsDPLA. 4-h supernatants were harvested and assayed for TNF activity (Fig. 2 A). RsDPLA (10-1,000 ng/ml) potently inhibited taxol-induced TNF secretion. We next determined if the ability of RsDPLA to block taxol was specific to RsDPLA or general to LPS antagonists. SDZ 880.431 was selected for testing due to its structural dissimilarity to RsDPLA. SDZ 880.431 effectively inhibited taxol-induced TNF over a concentration range of 0.3-10 μg/ml (Fig. 2 B). The concentrations of RsDPLA and SDZ 880.431 found to inhibit taxol-induced TNF were virtually identical to the concentrations required to block LPS (1 ng/ml)-induced macrophage TNF secretion and gene expression (22a). Although the taxol solutions contained no detectable activity in the Limulus amoebocyte lysate assay (see Materials and Methods), the ability of polymyxin B to block taxol-induced TNF was tested to control for the presence of endotoxin (Fig. 2 C). Polymyxin B inhibited the TNF-inducing activity of 1 ng/ml LPS, but had no effect on a submaximal concentration of taxol (16 μM).

Taxol-induced Gene Expression and Tyrosine Phosphorylation Is Blocked by Lipid A-based LPS Inhibitors. Taxol induces the expression of TNF-α and at least five other LPS-inducible genes (18). We next sought to determine if RsDPLA blocks taxol-induced TNF-α at the level of mRNA induction, and, if so, whether blockade of taxol-induced responses is selective or extends to the other inducible genes. Fig. 3 shows that RsDPLA inhibited taxol-induced expression of TNF-α and IL-1β mRNAs. In addition, RsDPLA inhibited the taxol-induced expression of transcripts encoding IFN-10, TNFR-2, D3, and D8, and taxol-induced expression of this entire panel of genes was similarly blocked by 0.3-10 μg/ml SDZ 880.431 (data not shown). Inhibition of gene expression by RsDPLA appeared to be of a competitive nature since it could be overridden by increasing the concentration of taxol (Fig. 4).

One of the earliest biochemical events measurable during taxol and LPS signaling is tyrosine phosphorylation of 41.5-43-, and 47-kD proteins (Fig. 5, solid lines between the two panels). This is accompanied by the apparent dephosphory-
Polymyxin B (pg/ml)

Polymyxin B (μg/ml)

Polymyxin B (ng/ml)

Polymyxin B (ng/ml)

Polymyxin B (μg/ml)

Polymyxin B (ng/ml)

Polymyxin B (μg/ml)

Polymyxin B (ng/ml)

Polymyxin B (μg/ml)

Polymyxin B (ng/ml)

Polymyxin B (μg/ml)

Polymyxin B (ng/ml)

Polymyxin B (μg/ml)

Polymyxin B (ng/ml)

Polymyxin B (μg/ml)

Polymyxin B (ng/ml)

Polymyxin B (μg/ml)

Polymyxin B (ng/ml)

Polymyxin B (μg/ml)

Polymyxin B (ng/ml)

Polymyxin B (μg/ml)

Polymyxin B (ng/ml)

Polymyxin B (μg/ml)

Polymyxin B (ng/ml)

Polymyxin B (μg/ml)

Polymyxin B (ng/ml)

Polymyxin B (μg/ml)

Polymyxin B (ng/ml)

Polymyxin B (μg/ml)

Polymyxin B (ng/ml)

Polymyxin B (μg/ml)

Polymyxin B (ng/ml)

Polymyxin B (μg/ml)

Polymyxin B (ng/ml)

Polymyxin B (μg/ml)

Polymyxin B (ng/ml)

Polymyxin B (μg/ml)

Polymyxin B (ng/ml)

Polymyxin B (μg/ml)

Polymyxin B (ng/ml)

Polymyxin B (μg/ml)

Polymyxin B (ng/ml)

Polymyxin B (μg/ml)

Polymyxin B (ng/ml)

Polymyxin B (μg/ml)

Polymyxin B (ng/ml)

Polymyxin B (μg/ml)

Polymyxin B (ng/ml)

Polymyxin B (μg/ml)

Polymyxin B (ng/ml)

Polymyxin B (μg/ml)

Polymyxin B (ng/ml)

Polymyxin B (μg/ml)

Polymyxin B (ng/ml)

Polymyxin B (μg/ml)

Polymyxin B (ng/ml)

Polymyxin B (μg/ml)

Polymyxin B (ng/ml)

Polymyxin B (μg/ml)

Polymyxin B (ng/ml)

Polymyxin B (μg/ml)

Polymyxin B (ng/ml)

Polymyxin B (μg/ml)

Polymyxin B (ng/ml)

Polymyxin B (μg/ml)

Polymyxin B (ng/ml)

Polymyxin B (μg/ml)

Polymyxin B (ng/ml)

Polymyxin B (μg/ml)

Polymyxin B (ng/ml)

Polymyxin B (μg/ml)

Polymyxin B (ng/ml)

Polymyxin B (μg/ml)

Polymyxin B (ng/ml)

Polymyxin B (μg/ml)

Polymyxin B (ng/ml)

Polymyxin B (μg/ml)

Polymyxin B (ng/ml)

Polymyxin B (μg/ml)

Polymyxin B (ng/ml)

Polymyxin B (μg/ml)

Polymyxin B (ng/ml)

Polymyxin B (μg/ml)

Polymyxin B (ng/ml)

Polymyxin B (μg/ml)

Polymyxin B (ng/ml)

Polymyxin B (μg/ml)

Polymyxin B (ng/ml)

Polymyxin B (μg/ml)

Polymyxin B (ng/ml)

Polymyxin B (μg/ml)

Polymyxin B (ng/ml)

Polymyxin B (μg/ml)

Polymyxin B (ng/ml)

Polymyxin B (μg/ml)

Polymyxin B (ng/ml)

Polymyxin B (μg/ml)

Polymyxin B (ng/ml)

Polymyxin B (μg/ml)

Polymyxin B (ng/ml)

Polymyxin B (μg/ml)

Polymyxin B (ng/ml)

Polymyxin B (μg/ml)

Polymyxin B (ng/ml)

Polymyxin B (μg/ml)

Polymyxin B (ng/ml)

Polymyxin B (μg/ml)

Polymyxin B (ng/ml)

Polymyxin B (μg/ml)

Polymyxin B (ng/ml)

Polymyxin B (μg/ml)

Polymyxin B (ng/ml)

Polymyxin B (μg/ml)

Polymyxin B (ng/ml)

Polymyxin B (μg/ml)

Polymyxin B (ng/ml)

Polymyxin B (μg/ml)

Polymyxin B (ng/ml)

Polymyxin B (μg/ml)

Polymyxin B (ng/ml)

Polymyxin B (μg/ml)

Polymyxin B (ng/ml)

Polymyxin B (μg/ml)

Polymyxin B (ng/ml)

Polymyxin B (μg/ml)

Polymyxin B (ng/ml)

Polymyxin B (μg/ml)

Polymyxin B (ng/ml)

Polymyxin B (μg/ml)

Polymyxin B (ng/ml)

Polymyxin B (μg/ml)

Polymyxin B (ng/ml)

Polymyxin B (μg/ml)

Polymyxin B (ng/ml)

Polymyxin B (μg/ml)

Polymyxin B (ng/ml)

Polymyxin B (μg/ml)

Polymyxin B (ng/ml)

Polymyxin B (μg/ml)

Polymyxin B (ng/ml)

Polymyxin B (μg/ml)

Polymyxin B (ng/ml)

Polymyxin B (μg/ml)

Polymyxin B (ng/ml)

Polymyxin B (μg/ml)

Polymyxin B (ng/ml)

Polymyxin B (μg/ml)

Polymyxin B (ng/ml)

Polymyxin B (μg/ml)

Polymyxin B (ng/ml)

Polymyxin B (μg/ml)

Polymyxin B (ng/ml)

Polymyxin B (μg/ml)

Polymyxin B (ng/ml)

Polymyxin B (μg/ml)

Polymyxin B (ng/ml)

Polymyxin B (μg/ml)

Polymyxin B (ng/ml)

Polymyxin B (μg/ml)

Polymyxin B (ng/ml)

Polymyxin B (μg/ml)

Polymyxin B (ng/ml)

Polymyxin B (μg/ml)

Polymyxin B (ng/ml)

Polymyxin B (μg/ml)

Polymyxin B (ng/ml)

Polymyxin B (μg/ml)

Polymyxin B (ng/ml)

Polymyxin B (μg/ml)

Polymyxin B (ng/ml)

Polymyxin B (μg/ml)

Polymyxin B (ng/ml)

Polymyxin B (μg/ml)

Polymyxin B (ng/ml)

Polymyxin B (μg/ml)

Polymyxin B (ng/ml)

Polymyxin B (μg/ml)

Polymyxin B (ng/ml)

Polymyxin B (μg/ml)

Polymyxin B (ng/ml)

Polymyxin B (μg/ml)

Polymyxin B (ng/ml)

Polymyxin B (μg/ml)

Polymyxin B (ng/ml)

Polymyxin B (μg/ml)

Polymyxin B (ng/ml)

Polymyxin B (μg/ml)

Polymyxin B (ng/ml)

Polymyxin B (μg/ml)

Polymyxin B (ng/ml)

Polymyxin B (μg/ml)

Polymyxin B (ng/ml)

Polymyxin B (μg/ml)

Polymyxin B (ng/ml)

Polymyxin B (μg/ml)

Polymyxin B (ng/ml)

Polymyxin B (μg/ml)

Polymyxin B (ng/ml)

Polymyxin B (μg/ml)

Polymyxin B (ng/ml)

Polymyxin B (μg/ml)

Polymyxin B (ng/ml)

Polymyxin B (μg/ml)

Polymyxin B (ng/ml)

Polymyxin B (μg/ml)

Polymyxin B (ng/ml)

Polymyxin B (μg/ml)

Polymyxin B (ng/ml)

Polymyxin B (μg/ml)

Polymyxin B (ng/ml)

Polymyxin B (μg/ml)

Polymyxin B (ng/ml)

Polymyxin B (μg/ml)

Polymyxin B (ng/ml)

Polymyxin B (μg/ml)

Polymyxin B (ng/ml)

Polymyxin B (μg/ml)

Polymyxin B (ng/ml)

Polymyxin B (μg/ml)

Polymyxin B (ng/ml)

Polymyxin B (μg/ml)

Polymyxin B (ng/ml)
Figure 4. Raising the concentration of taxol overrides RsDPLA inhibition of TNF-α mRNA. C3H/OuJ macrophages were cultured 4 h with media alone or containing 20 ng/ml RsDPLA and increasing concentrations of taxol. Cellular RNA was harvested and subjected to Northern blot analysis of TNF-α and β-actin gene expression. Relative gene expression was determined by Phosphorimaging as described in Materials and Methods.

index," can be determined by counting the percentage of cells that contain mitotic spindles. By stabilizing microtubules, taxol induces the formation of multiple, dysfunctional mitotic asters and blocks progression through mitosis. Consequently, RAW 264.7 cells that contain mitotic spindles or asters accumulated sevenfold when cultured 4 h in the presence of taxol. As shown in Table 1, excess RsDPLA or SDZ 880.431 did not reduce the percentage of cells blocked in mitosis by taxol. These results confirm that RsDPLA or SDZ 880.431 do not inhibit taxol-mediated microtubule stabilization.

**Taxotere Stabilizes Microtubules but Fails to Induce TNF Secretion or Gene Activation.** Taxotere is a semisynthetic taxoid that is two- to threefold more potent than taxol as a microtubule stabilizing agent (15). In our experiments, bundling and aster formation in RAW 264.7 cells was induced by as little as 0.075 μM taxotere, while 0.3 μM taxol was required to achieve a comparable effect. To investigate further the relationship between microtubule stabilization and cell signaling, the ability of taxotere to induce murine macrophages to secrete TNF and express TNF-α mRNA was examined (Fig. 6). Taxotere did not induce detectable TNF secretion or mRNA expression.

**Discussion**

Taxol-induced TNF secretion, gene activation, and protein-tyrosine phosphorylation were blocked by 10-1,000 ng/ml RsDPLA or 0.3-10 μg/ml SDZ 880.431. These concentrations of RsDPLA and SDZ 880.431 inhibit LPS responses...
Taxol, by virtue of its effects on microtubules, might permit microtubule-dependent signaling. However, induction of TNF may not be required to determine if crosslinking derivatives of taxol retain LPS-mimetic activity, and to apply these derivatives to the identification of novel proteins that may also bind LPS and lipid A-based LPS inhibitors. Taxol represents the first of a class of new anticancer drugs, and much may be learned regarding tumor biology and treatment as the pharmacology of these agents is more completely understood. The mechanism of action of this group of agents is felt to reside in their ability to stabilize microtubules and prevent cell progression through mitosis. Our results suggest taxol may also activate putative LPS receptors on murine macrophages. For decades investigators have known that LPS can cure rodents of tumors (38, 39), but the use of LPS in humans is confounded by its unacceptable toxicity. Antitumor activity of LPS arises, in part, from the ability of LPS to induce TNF and other cytokines and to serve as a second signal in the activation of macrophage nitric oxide synthase and tumoricidal activity (39, 40). LPS substructures have been identified that are relatively nontoxic, but that retain the antitumor activity of LPS (39). Two such compounds, monophosphoryl lipid A and SDZ MRL 953, activate murine macrophages in an LPS-like fashion and are blocked by lipid A-based inhibitors (29, 31). We propose that taxol, by analogy to these nontoxic LPS mimetics, may activate host antitumor activity. However, induction of TNF may not be required for the therapeutic efficacy of other taxoids. Although taxotere did not induce TNF in murine macrophages, recent phase II clinical trials indicate that taxotere is a highly effective drug against breast cancer and other solid tumors (16). More work is required to determine if taxol can act as a second signal for induction of tumoricidal activity and to determine the cell specificity of the LPS-mimetic actions of taxol, e.g., it will be important to determine if taxol stimulates cell types other than macrophages, and if taxol activates genes in human immune or neoplastic tissues.
We thank P.-Y. Perera for assaying samples for TNF activity.

This work was supported by National Institutes of Health (NIH) grants AI-18797 (S. N. Vogel) and AI-08451 (C. Manthey). The opinions or assertions contained within are the private views of the authors and should not be construed as official or necessarily reflecting the view of the Uniformed Services University of the Health Sciences or the Department of Defense. Research was conducted according to the principles enunciated in “Guide for the Care and Use of Laboratory Animals” prepared by the Institute of Laboratory Animal Resources, National Research Council, Department of Health, Education and Welfare, publication no. (NIH) 85-23.

Address correspondence to Stefanie N. Vogel, Department of Microbiology, Uniformed Services University of the Health Sciences, 4301 Jones Bridge Road, Bethesda, MD 20814-4799.

Received for publication 21 April 1993 and in revised form 25 May 1993.

References

1. Nowotny, A. 1990. Immune reactions elicited or modulated by endotoxin. In Endotoxin Research Series, Vol. 1. Cellular and Molecular Aspects of Endotoxin Reactions. A. Nowotny, J.J., Spitzer, and E.J. Ziegler, editors. Excerpta Medica, Inc., Belle Mead, NJ 329-338.

2. Parker, M.M., and J.E. Parrillo. 1983. Septic shock: Hemodynamics and pathogenesis. J. Am. Med. Assoc. 250:3324.

3. Manthey, C.L., and S.N. Vogel. 1993. Interactions of lipopolysaccharide with macrophages. In Macrophage Pathogen Interactions. B.S. Zwilling and T.K. Eisenstein, editors. Marcel Dekker, Inc., New York. 63-81.

4. Raetz, C.R.H., R.J. Ulevitch, S.D. Wright, C.H. Sibley, A. Ding, and C.F. Nathan. 1991. Gram-negative endotoxin: an extraordinary lipid with profound effects on eukaryotic signal transduction. FASEB (Fed. Am. Soc. Exp. Biol.) J. 5:2652.

5. Schumann, R.R., S.R. Leong, G.W. Flaggs, P.W. Gray, S.D. Wright, J.C. Mathison, P.S. Tobias, and R.J. Ulevitch. 1990. Structure and function of lipopolysaccharide binding protein. Science (Wash. DC). 249:1429.

6. Wright, S.D., R.A. Ramos, M. Patel, and D.S. Miller. 1992. Septin: a factor in plasma that opsonizes lipopolysaccharide-bearing particles for recognition by CD14 on phagocytes. J. Exp. Med. 176:719.

7. Tobias, P.S., K. Soldau, L. Kline, J.-D. Lee, K. Kato, T.P. Martin, and R.J. Ulevitch. 1993. Crosslinking of lipopolysaccharide to CD14 on THP-1 cells mediated by lipopolysaccharide binding protein. J. Immunol. In press.

8. Wright, S.D., R.A. Ramos, P.S. Tobias, R.J. Ulevitch, and J.C. Mathison. 1990. CD14, a receptor for complexes of lipopolysaccharide (LPS) and LPS binding protein. Science (Wash. DC). 249:1431.

9. Kitchens, R.L., R.J. Ulevitch, and R.S. Munford. 1992. Lipopolysaccharide (LPS) partial structures inhibit responses to LPS in a human macrophage cell line without inhibiting LPS uptake by a CD14-mediated pathway. J. Exp. Med. 176:485.

10. Rowinsky, E.K., N. Onetto, R.M. Canetta, and S.G. Arbuck. 1992. Taxol: the first of the taxanes, an important new class of antitumor agents. Semin. Oncol. 19:546.

11. Manfredi, J.J., J. Parness, and S.B. Horwitz. 1982. Taxol binds to cellular microtubules. J. Cell Biol. 94:688.

12. Rao, S., S.B. Horwitz, and I. Ringer. 1992. Direct photoaffinity labeling of tubulin with taxol. J. Natl. Cancer Inst. 84:785.

13. Kingston, D.G.I. 1991. The chemistry of taxol. Pharmac. Ther. 52:1.
response and inhibition by lipid A-based antagonists. J. Immunol. 147:3072.
25. Van Dervort, A.L., M.E. Doerfler, P. Stuetz, and R.L. Danner. 1992. Antagonism of lipopolysaccharide-induced priming of human neutrophils by lipid A analogs. J. Immunol. 149:359.
26. Takayama, K., N. Qureshi, B. Beutler, and T.N. Kirkland. 1989. Diprophosphoryl lipid A from Rhodopseudomonas sphaeroides ATCC 17023 blocks induction of cachectin in macrophages by lipopolysaccharide. Infect. Immun. 57:1336.
27. Qureshi, N., K. Takayama, K.C. Meyers, T.N. Kirkland, C.A. Bush, L. Chen, R. Wang, and R.J. Cotter. 1991. Chemical reduction of 3-oxo unsaturated groups in fatty acids of diprophosphoryl lipid A from the lipopolysaccharide of Rhodopseudomonas sphaeroides: comparison of biological properties before and after reduction. J. Biol. Chem. 266:6532.
28. Qureshi, N., K. Takayama, and R. Kurtz. 1991. Diprophosphoryl lipid A obtained from the nontoxic lipopolysaccharide of Rhodopseudomonas sphaeroides is an endotoxin antagonist in mice. Infect. Immun. 59:441.
29. Henriksson, B.E., P.-Y. Perera, N. Qureshi, K. Takayama, and S.N. Vogel. 1992. Rhodopseudomonas sphaeroides lipid A derivatives block in vitro induction of TNF and endotoxin tolerance by smooth LPS and monophosphoryl lipid A. Infect. Immun. 60:4285.
30. Stuetz, P.L., H. Aschauer, J. Hildebrandt, C. Lam, H. Loibner, I. Mach, D. Scholz, E. Schuetze, and H. Vyplel. Chemical synthesis of endotoxin analogues and some structure activity relationships. In Endotoxin Research Series, Vol. 1. Cellular and Molecular Aspects of Endotoxin Reactions. A. Nowotny, J.J. Spitzer, and E.J. Ziegler, editors. Excerpta Medica, Inc., Belle Mead, NJ. 129–144.
31. Perera, P.-Y., C.L. Manthey, P.L. Stuetz, and S.N. Vogel. 1993. Induction of early gene expression in murine macrophages by toxic and non-toxic synthetic lipid A analogues. Infect. Immun. 61:2015.
32. McIntyre, F.C., H.W. Sievert, G.H. Barlow, R.A. Finley, and A.Y. Lee. 1967. Chemical, physical, and biological properties of a lipopolysaccharide from Escherichia coli K-235. Biochemistry. 6:2363.
33. Pennica, D., J.S. Hayflick, T.S. Bringman, M.A. Palladino, and D.V. Goeddel. 1985. Cloning and expression in Escherichia coli of the cDNA for murine tumor necrosis factor. Proc. Natl. Acad. Sci. USA. 82:6060.
34. Tokunaga, K., H. Taniguchi, K. Yoda, M. Shimizu, and S. Sakiyama. 1986. Nucleotide sequence of a full-length cDNA for mouse cytoskeletal β-actin mRNA. Nucleic Acids Res. 14:2829.
35. Tannenbaum, C.S., T.J. Koerner, M.M. Jansen, and T.A. Hamilton. 1988. Characterization of lipopolysaccharide-induced macrophage gene expression. J. Immunol. 140:3640.
36. Ding, A.H., F. Porteu, E. Sanchez, and C.F. Nathan. 1990. Downregulation of tumor necrosis factor receptors on macrophages and endothelial cells by microtubule depolymerizing agents. J. Exp. Med. 171:715.
37. Lei, M.-G., and D.C. Morrison. 1988. Specific endotoxic lipopolysaccharide-binding proteins on murine splenocytes. I. Detection of lipopolysaccharide-binding sites on splenocytes and splenocyte subpopulations. J. Immunol. 141:996.
38. Shear, M.J., F.C. Turner, A. Perrault, and T. Shovelton. 1943. Chemical treatment of tumors. V. Isolation of the hemmorrhage-producing fraction from Serratia marcescens (Bacillus prodigiosus) culture filtrate. J. Natl. Cancer Inst. 4:81.
39. Jeannin, J.-F., N. Onier, P. Lagadec, N. von Jeney, P. Stuetz, and E. Liehl. 1991. Antitumor effect of synthetic derivatives of lipid A in an experimental model of colon cancer in the rat. Gastroenterology. 101:726.
40. Lorsbach, R.B., W.J. Murphy, C.J. Lowenstein, S.H. Snyder, and S.W. Russell. 1993. Expression of the nitric oxide synthase gene in mouse macrophages activated for tumor cell killing: molecular basis for the synergy between interferon-γ and lipopolysaccharide. J. Biol. Chem. 268:1908.